Cancer Research Articles

During the 2023 Florida Society of Clinical Oncology (FLASCO) Fall Session, several Florida Cancer Specialists & Research Institute, LLC (FCS) physicians were elected to serve as executive committee officers and chairs for the nationally recognized advocacy group in the upcoming term beginning January 1, 2024.

FCS physicians present at the Society for Immunotherapy of Cancer Annual Meeting in San Diego.

FCS is now offering an advanced maintenance therapy program that slows the progression of relapsed/refractory multiple myeloma (RRMM). The treatment, teclistamab (TECVAYLI®), is a type of rapidly evolving cancer therapy that uses the body’s immune system to fight cancer.

Pharmacy experts and leaders from Florida Cancer Specialists & Research Institute, LLC (FCS) are contributing to improving cancer care globally as they join fellow oncology professionals for the NCODA 2023 International Fall Summit in Orlando this week.

Research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is featured this week among the latest advancements and findings in cancer care at the European Society of Medical Oncology (ESMO) Congress in Madrid, Spain.

FCS clinicians and senior leaders are among the industry experts who will present breakthrough data, research and clinical strategies at the Florida Society of Clinical Oncology (FLASCO) Fall Session in Orlando this month.

Executive leaders of Florida Cancer Specialists & Research Institute (FCS) will serve on the faculty for the Association for Value-Based Cancer Care 2023 Summit & Educational Program in New York, NY on Oct. 18 – 20.

A best practice clinical program developed by FCS is ensuring that patients with certain blood disorders achieve maximum clinical benefits from the use of oral medications.